The 17-hydroxyprogesterone (17-OHP) test measures a steroid made mainly in the adrenal glands and, to a smaller extent, the ovaries and testes. Its main use is screening for or evaluating congenital adrenal hyperplasia (CAH), especially 21-hydroxylase deficiency. It may also be ordered when acne, excess facial or body hair, irregular periods, early puberty, infertility, or an adrenal disorder raises concern about excess androgen production. A mildly elevated result does not automatically mean CAH: timing, stress, pregnancy, medicines, menstrual phase, and the laboratory method can all affect the number. Morning sampling and, for menstruating patients, early-follicular timing make a borderline result easier to interpret. When the baseline level falls in an intermediate range, an ACTH stimulation test may be needed. Newborn screening, childhood testing, and adult evaluation use different cutoffs, so the report’s age- and method-specific interval matters.
- 17-OHP is primarily a screening and follow-up marker for 21-hydroxylase-deficient congenital adrenal hyperplasia.
- A morning sample is preferred; in menstruating adults, testing early in the follicular phase reduces false elevations.
- A basal result below about 200 ng/dL often makes nonclassic CAH less likely, but cutoffs vary by assay.
- Borderline or intermediate results commonly require an ACTH stimulation test rather than immediate diagnosis.
- PCOS can cause a mild 17-OHP increase, but marked or stimulated elevation raises greater concern for CAH.
- Urgent assessment is needed for vomiting, dehydration, low blood pressure, severe weakness, or suspected adrenal crisis.
Table of Contents
- What the 17-OHP Test Measures
- Why the Test Is Ordered
- Preparation, Timing, and the Testing Process
- Normal Range and How Results Are Interpreted
- What High 17-OHP Results Can Mean
- What Low 17-OHP Results Can Mean
- How Results Fit With Other Hormones and Tests
- Next Steps After the Result
What the 17-OHP Test Measures
17-OHP is an intermediate in the pathway that converts cholesterol into cortisol and other adrenal steroids. The enzyme 21-hydroxylase normally moves much of this intermediate toward cortisol. When that enzyme works poorly, 17-OHP accumulates and more steroid material is redirected toward androgen production.
Classic CAH usually presents in infancy or childhood and can include salt-wasting, atypical genital development, rapid growth, or early androgen effects. Nonclassic CAH is milder and may first appear in adolescence or adulthood with hirsutism, acne, irregular ovulation, or infertility. The same marker is therefore used in very different clinical settings, with different decision limits.
A hormone result is a measurement made under defined laboratory conditions, not a diagnosis by itself. The same concentration can carry different meaning at different ages, cycle stages, pregnancy stages, or times of day. Laboratories also use different analyzers, calibration systems, antibodies, and calculation methods. For that reason, the reference interval printed beside the result should take priority over a range copied from another report or website.
17-OHP is not the same as progesterone. Both are steroid hormones, but they occupy different points in steroid synthesis and answer different clinical questions. A standard progesterone result cannot substitute for 17-OHP when CAH is suspected.
When several adrenal steroids are abnormal, a broader CAH hormone panel can help identify the affected pathway.
Why the Test Is Ordered
Clinicians order 17-OHP when symptoms or screening results suggest excess adrenal androgens or impaired cortisol synthesis. The test may be a first-line measurement, a confirmation step after newborn screening, or part of ongoing CAH monitoring.
- An abnormal newborn CAH screen or a newborn with poor feeding, vomiting, dehydration, or atypical genital development.
- Rapid childhood growth, advanced bone age, premature pubic hair, or other early androgen effects.
- Hirsutism, persistent acne, irregular or absent periods, or infertility that could reflect nonclassic CAH.
- Distinguishing nonclassic CAH from PCOS or another source of androgen excess.
- Monitoring treatment in a person with established 21-hydroxylase deficiency, together with clinical growth and androgen markers.
A screening result cannot show the exact genetic variant or predict severity on its own. Confirmed CAH may require electrolytes, renin, cortisol, androstenedione, testosterone, genetic testing, and clinical assessment. In newborns, prematurity and illness can raise 17-OHP and increase false-positive screening results.
Interpretation starts with the reason the test was ordered. A clinician looking for an adrenal enzyme disorder uses different cutoffs and follow-up tests than a clinician evaluating irregular periods, infertility, menopausal symptoms, or androgen deficiency. The result should be read with symptoms, examination findings, age, reproductive stage, and related laboratory values rather than compared with one universal “optimal” number.
Adults with androgen excess are often assessed with a PCOS hormone panel as well as targeted testing for adrenal causes.
Preparation, Timing, and the Testing Process
The most interpretable baseline sample is usually collected in the morning, when ACTH-driven adrenal steroid production is higher and testing protocols are standardized.
- Confirm whether the order is for a basal 17-OHP measurement or an ACTH stimulation test.
- Schedule a morning blood draw; if periods occur, ask whether cycle days 3–5 or another early-follicular day is preferred.
- List glucocorticoids, fertility medicines, hormonal contraception, progesterone, and supplements.
- Do not stop steroid replacement or other prescribed hormones unless the ordering clinician gives a specific plan.
- Tell the laboratory about pregnancy, acute illness, prematurity, or major stress because these can change interpretation.
For an ACTH stimulation test, blood is drawn before synthetic ACTH and again at a defined interval, commonly 30 or 60 minutes. The laboratory and clinic must use a validated protocol and method-specific cutoff. Sampling in the luteal phase can produce a higher baseline because ovarian steroid production increases after ovulation.
Before collection, provide a complete list of prescription medicines, over-the-counter products, supplements, contraceptives, fertility drugs, and hormone therapy. Do not stop prescribed treatment without instructions. Some products change hormone production, while others alter binding proteins or interfere with an immunoassay. High-dose biotin is a well-known source of interference in several hormone tests, although the direction and size of the error depend on the platform.
Acute illness can temporarily suppress or stimulate reproductive signaling. A test drawn during fever, major surgery, severe calorie restriction, or intense training may describe that temporary state rather than the person’s usual hormone function. When the clinical situation is stable and there is no urgent reason to test immediately, postponing or repeating the measurement can prevent an incorrect label.
Normal Range and How Results Are Interpreted
No single 17-OHP range applies to every age or assay. The following guide describes common adult screening logic in conventional units; it is not a replacement for the report or a stimulation-test protocol.
| Result pattern | Typical interpretation | Common next step |
|---|---|---|
| Below about 200 ng/dL (about 6 nmol/L) | Nonclassic 21-hydroxylase deficiency is less likely when sampling is appropriate. | Consider other causes if symptoms persist. |
| About 200–1,000 ng/dL (about 6–30 nmol/L) | Intermediate; overlap occurs with PCOS, luteal-phase sampling, and carriers. | Repeat correctly timed testing or perform ACTH stimulation. |
| Above about 1,000 ng/dL (about 30 nmol/L) | Strongly abnormal in many adult protocols, though method and context still matter. | Urgent endocrine review and confirmatory evaluation. |
| Elevated after ACTH stimulation | May meet criteria for nonclassic CAH when the assay-specific threshold is exceeded. | Endocrine assessment, possible genetic testing, and counseling. |
Newborn values are much higher than adult values and depend heavily on birth weight and gestational age. Children also require age- and puberty-specific intervals. Immunoassays may read higher than liquid chromatography–tandem mass spectrometry because related steroids can cross-react.
A value close to a cutoff deserves more caution than a value that is clearly and repeatedly abnormal. Borderline results may move across the reference limit because of normal biologic variation, recent illness, sleep disruption, exercise, stress, or sample timing. Clinicians often repeat a test under better-controlled conditions before ordering imaging or beginning treatment. The repeat is most useful when the timing, medication list, and assay method are documented.
Trends can be useful when the same question is followed over time, but only when the measurements are reasonably comparable. A change between laboratories may reflect a method difference. A change after starting or stopping hormones may be expected. Record the laboratory, units, collection time, cycle day or pregnancy week, and relevant treatment so later results can be compared in context.
What High 17-OHP Results Can Mean
A high 17-OHP result means that more of this steroid intermediate is present than expected for the testing context. The degree of elevation, symptoms, and response to ACTH help separate common mild causes from CAH.
- Classic or nonclassic 21-hydroxylase deficiency.
- Testing during the luteal phase, pregnancy, acute illness, or significant physical stress.
- PCOS or another condition with increased ovarian or adrenal androgen production.
- Certain adrenal tumors or uncommon steroid-enzyme disorders.
- Glucocorticoid under-replacement, missed doses, or poor absorption in a person with known CAH.
- Assay cross-reactivity or an age-inappropriate reference interval.
In nonclassic CAH, the baseline result may be only modestly elevated. A stimulated result and the overall phenotype carry more weight than one basal number. Treatment is not automatic: some people with biochemical nonclassic CAH have few symptoms and do not need glucocorticoids.
In established CAH, driving 17-OHP fully into the normal range can indicate excessive glucocorticoid treatment. Monitoring aims to control androgen excess while avoiding growth suppression, weight gain, hypertension, low bone density, and other effects of over-replacement.
A marked result, especially with low sodium, high potassium, dehydration, or hypotension, requires prompt clinical assessment. In a stable adult with a borderline value, correct timing and confirmation are usually more informative than immediate imaging.
What Low 17-OHP Results Can Mean
A low 17-OHP result is usually not a problem by itself. It can reflect normal physiology, suppression of adrenal steroid production, or effective glucocorticoid treatment.
- Normal low baseline production outside the newborn period.
- Glucocorticoid treatment, including hydrocortisone, prednisone, or dexamethasone.
- Suppression from other hormone therapy or severe chronic illness.
- Adrenal insufficiency affecting several adrenal steroids, usually with low cortisol and compatible symptoms.
- A sample collected at a time when adrenal drive is lower.
For a person without known adrenal disease, an isolated low value rarely explains symptoms. Cortisol and ACTH are the more direct tests when adrenal insufficiency is suspected. In treated CAH, a very low 17-OHP together with Cushing-like effects may suggest overtreatment, but dose changes should be based on the full monitoring picture.
Do not increase supplements or alter steroid doses because of a low 17-OHP number alone. Review the treatment schedule, symptoms, growth, blood pressure, and related hormones with the prescribing clinician.
How Results Fit With Other Hormones and Tests
17-OHP becomes more informative when paired with cortisol, ACTH, and androgen results. Patterns can suggest where steroid synthesis is being diverted and whether a dynamic test is needed.
| 17-OHP pattern | Related findings | Possible explanation |
|---|---|---|
| Markedly high | Androstenedione/testosterone high; cortisol response impaired | 21-hydroxylase deficiency |
| Mildly high | Androgens mildly high; irregular periods; normal stimulated result | PCOS, timing effect, or assay variation |
| High in a newborn screen | Prematurity, low birth weight, or illness present | False-positive screen remains possible; confirm promptly |
| Low during treatment | Androgens low; glucocorticoid effects present | Possible over-suppression |
| Low with low cortisol | ACTH may be high or low depending on cause | Adrenal or pituitary evaluation may be needed |
Electrolytes and plasma renin are especially important in salt-wasting CAH. Genetic testing can confirm CYP21A2 variants, support family counseling, and clarify uncertain biochemical results, but it does not replace urgent treatment when an infant is clinically unstable.
Next Steps After the Result
The next step depends on whether the result came from newborn screening, an androgen-excess workup, or monitoring of known CAH.
- Verify the sample time, cycle phase, age-specific interval, units, and assay method.
- Repeat a borderline basal test in the morning and early follicular phase when appropriate.
- Use an ACTH stimulation test when the basal result falls in an intermediate range or suspicion remains high.
- Measure related hormones and electrolytes according to the presentation.
- Refer confirmed or strongly suspected CAH to endocrinology; involve reproductive specialists when fertility or pregnancy is a concern.
- Create a sick-day and emergency steroid plan for anyone with cortisol deficiency.
People with classic CAH need education about stress dosing and emergency hydrocortisone. Those planning pregnancy may need genetic counseling because CAH is inherited in an autosomal recessive pattern. For nonclassic CAH, treatment is usually guided by symptoms, ovulation, fertility goals, and androgen excess rather than the laboratory value alone.
Bring the actual report to the follow-up visit rather than only recalling that the level was “high” or “low.” The report shows units, the laboratory interval, specimen type, and sometimes the assay method. Ask whether the result needs confirmation, whether a related hormone should be measured at the same time, and what finding would change management.
A useful plan defines the next step and its timing. That may be no action, a repeat test, a dynamic stimulation or suppression test, ultrasound, semen analysis, genetic testing, or referral to endocrinology, reproductive endocrinology, urology, or maternal-fetal medicine. It should also identify symptoms that warrant earlier contact instead of waiting for the routine appointment.
Rapidly progressive symptoms deserve faster evaluation than a mild, stable laboratory abnormality. Examples include sudden virilization, severe headache with visual change, signs of adrenal crisis, heavy bleeding with dizziness, or concerning pregnancy symptoms. The laboratory number may guide the workup, but urgent decisions are driven by the whole clinical picture.
Treatment should address the confirmed cause and the person’s goals. Lowering or raising a laboratory value without establishing why it is abnormal can hide an important condition or create new problems. Hormone therapy can affect fertility, blood counts, liver function, clot risk, bone health, and pregnancy, so monitoring plans should be individualized.
Seek urgent care for repeated vomiting, severe weakness, dehydration, confusion, fainting, low blood pressure, or inability to take prescribed glucocorticoids. These can signal adrenal crisis, which requires immediate treatment.
When a repeat measurement is planned, try to reproduce the conditions that matter for this test. Use the same laboratory when practical, note the collection time, and record any change in medicines or reproductive stage. Consistency does not remove all biologic variation, but it makes a true trend easier to distinguish from noise.
Reference intervals describe a population selected by the laboratory; they do not define a treatment target for every person. A result inside the interval can still require attention when symptoms are strong or when another hormone shows a clear mismatch. Conversely, a small deviation may not represent disease when the timing or clinical setting explains it.
A laboratory result can answer only the question built into the test. It may show hormone concentration, but it cannot by itself prove ovulation quality, egg quality, sperm production, placental health, or the cause of a symptom. Those conclusions usually require a combination of history, examination, imaging, and other targeted tests.
When fertility is the concern, age, duration of trying to conceive, menstrual pattern, pregnancy history, semen findings, and tubal or uterine factors often affect the plan as much as a single hormone value. Testing both partners in parallel can prevent months of delay and reduce the chance that an incidental hormone result distracts from a more direct cause.
When symptoms are being monitored rather than fertility, define the outcome that treatment is meant to improve. Examples include restoration of periods, relief of hot flashes, reduction of unwanted hair growth, recovery of sexual function, preservation of bone health, or safe progression of puberty. Laboratory monitoring is most useful when tied to one of these clinical outcomes.
People using nonprescription “hormone balance” products should mention them before testing. DHEA, progesterone creams, testosterone boosters, compounded preparations, and biotin can alter physiology or make results harder to interpret. Product labels may not reliably predict the dose absorbed, so the safest approach is to review the exact container or ingredient list with the clinician.
Results can also differ because laboratories report conventional and SI units. A value expressed in ng/dL cannot be compared directly with one expressed in nmol/L without a hormone-specific conversion. Always compare the number, unit, and interval together. This simple check prevents many apparent contradictions between reports.
An abnormal result can have emotional weight, especially during fertility treatment, pregnancy, or puberty evaluation. Ask the clinician to separate what is known from what remains uncertain. A clear explanation of the likely causes, the confirmation plan, and the time frame for action is more useful than trying to interpret every decimal place independently.
Clinicians also consider whether the test result agrees with the physical findings. A marked biochemical abnormality without expected symptoms may prompt confirmation with a more specific laboratory method. Strong symptoms with a normal result may lead to testing at a different time, measuring a related hormone, or looking for a nonhormonal cause.
The pace of change can be as important as the level itself. Slow changes over years commonly fit physiologic aging or a chronic endocrine condition. Changes over weeks or a few months raise more concern for a new medicine effect, pregnancy-related change, acute illness, or a hormone-producing lesion, especially when symptoms progress quickly.
No single follow-up pathway fits every abnormal value. Mild and explainable results may only need observation. Persistent or substantial abnormalities may require specialist review and tests chosen to locate the source of hormone production or the level of signaling failure. The sequence should be deliberate so that each test answers a specific unresolved question.
Keep a copy of the laboratory report and the order indication. The clinician needs more than the highlighted flag: the numeric value, unit, reference interval, specimen type, collection date and time, and any comment about the assay can change interpretation. A result copied into a patient portal message without those details may be impossible to compare with a later test. This documentation is especially important when care moves between a primary clinician, endocrinologist, fertility clinic, and hospital laboratory.
Before repeating testing, decide what the repeat is meant to resolve. It may confirm persistence, correct a timing error, remove a medication effect, or use a more specific assay. Repeating the same poorly timed test without changing the conditions often reproduces uncertainty rather than solving it. The clinician should also state what result would lead to observation, another laboratory test, imaging, or treatment.
Small deviations from a reference interval are common because the interval usually contains about 95% of a selected comparison population. Some healthy people fall outside it, while some people with disease fall inside it. The clinical importance depends on how far the value is from the limit, whether it persists, whether related hormones agree, and whether symptoms fit the physiology. A reference flag is therefore a prompt for interpretation, not proof of disease.
Hormone results are also affected by changes in binding proteins and metabolism. Liver disease, thyroid disease, kidney disease, pregnancy, body composition, and oral estrogen exposure can change measured concentrations without producing the same change in tissue effect. When a binding issue is suspected, the clinician may use a free or calculated hormone, a related binding protein, or a more specific laboratory method rather than interpreting the total concentration alone.
Fertility decisions should not be reduced to a single endocrine value. A hormone may help choose medication dose, confirm ovulation, or identify a treatable disorder, but it does not measure every step required for pregnancy. Reproductive age, sperm exposure or semen quality, tubal patency, uterine anatomy, timing, prior pregnancies, and the duration of trying all influence the next step. A balanced evaluation prevents overreaction to an incidental result.
References
- Congenital Adrenal Hyperplasia 2024 (Review)
- 21-Hydroxylase Deficiency 2025 (Review)
- Treatment and Follow-up of Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency in Childhood and Adolescence 2025 (Review)
- Molecular basis and genetic testing strategies for congenital adrenal hyperplasia caused by 21-hydroxylase deficiency 2023 (Review)
- Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women 2025 (Guideline)
Disclaimer
This article provides general information about 17-OHP testing and cannot diagnose CAH, PCOS, or adrenal disease. Newborn abnormalities and symptoms of adrenal crisis require prompt medical care. Do not change glucocorticoid treatment without the prescribing clinician.
